Business
USRM Responds to Lawsuit Filed for Discontinued Eye Treatments
USRM Responds to Lawsuit Filed for Discontinued Eye Treatments.
About this update from U.s. Stem Cell, Inc.
[{"type":"text","content":"\n\n\n\nUSRM Responds to Lawsuit Filed for Discontinued Eye Treatments\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nUSRM Responds to Lawsuit Filed for Discontinued Eye Treatments\nPR Newswire\nMIAMI, Dec. 20, 2017\n\n\n\nMIAMI, Dec. 20, 2017 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today responded to a lawsuit filed last week in Broward County by a plaintiff claiming she had an adverse event for a voluntary stem cell procedure at a doctor's office utilizing autologous (the patient's own) stem cells to attempt to reverse the effects of macular degeneration— a disease that currently has no cure. \n\nThe adverse event the plaintiff claims she experienced as a result of the treatment, which was administered by a doctor in February of 2015, is a detached retina in one eye, which the patient alleges has led to loss of sight in that eye. Counsel for the patient also claims that his client's vision has worsened in the other eye. As the lawsuit was just filed, these allegations have not been corroborated. USRM's AdipoCell™ kit was used to harvest autologous cells from the patient's fat tissue.\n\nThe use of autologous stem cells for macular degeneration was discontinued by US Stem Cell Clinic, a separate company, as of June of 2015, after adverse events were reported. \n\n\"We have addressed any concerns about using AdipoCell™ for macular degeneration by discontinuing its use since more than two years ago,\" said Dr. Kristin Comella, USRM's Chief Science Officer. \"Because we have seen strong safety profiles using AdipoCell™ to harvest autologous stem cells to treat a wide variety of other conditions — including orthopedic, autoimmune, degenerative and neurological diseases — we are instead focusing our development at this time on these more broad arenas.\"\n\n\"Publicly traded companies are always a target for law suits,\" said Mike Tomas, President & CEO of U.S. Stem Cell, Inc. \"Every lawsuit is...